(Q37678414)

21 August 2017

1 reference

title

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy (English)

1 reference

21 August 2017

1 reference

Robert J Amato

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

281-287

1 reference

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Nonreplicating vaccinia vector efficiently expresses recombinant genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903586213

10.1517/14712590903586213

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference